随着或没有系统疗法的切换,用于寡头进展的立体性身体放射疗法
Jonas Willmann1, Eugenia Vlaskou Badra1, Selma Adilovic1
1Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
Clinical and translational radiation oncology
|March 4, 2024
概括
寡进症,定义为治疗期间癌症进展有限,无论患者在刻板体辐射疗法 (SBRT) 后是否继续或切换全身疗法,都显示了类似的结果. 这表明,在某些情况下,可以安全地推迟治疗的继续.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 寡进症被定义为在积极的全身疗法下癌症进展的限制.
- 转移导向疗法 (立体体辐射疗法 - SBRT) 和系统疗法管理在寡头进展中的作用受到辩论.
- 这项研究研究了SBRT治疗的寡进性患者的结果,比较了系统治疗的延续与切换.
研究的目的:
- 评估和比较在SBRT后继续或切换系统治疗的寡进症患者的瘤学结果 (总生存率 - OS,无进展生存率 - PFS).
- 分析影响SBRT后生存的因素,以分析SBRT后生存的因素.
主要方法:
- 在2014年1月至2019年12月期间接受SBRT治疗的135名患有寡头进展的患者的回顾性分析.
- 根据SBRT后是否继续或切换全身治疗,患者被分类.
- 使用Kaplan-Meier分析了OS和PFS,使用累积发病率函数分析了下一个全身治疗的时间. 使用多变量考克斯回归.
主要成果:
- 在135名患者中,96人继续全身治疗,39人切换.
- 在SBRT后切换并继续全身治疗的患者的中位数OS (32.1个月与38.2个月) 和PFS (4.3个月与3.4个月) 相似.
- 2的ECOG性能状态和立即开始新的全身疗法与较差的生存率有关; de-novo寡头转移性疾病 (OMD) 状态与更好的生存率相关.
结论:
- 在SBRT后继续或切换系统治疗的患者之间,癌症结局与SBRT后继续或切换系统治疗的患者之间的结局相似.
- 这些发现表明,在精选的寡进患者中,可以安全地推迟开始进一步的全身疗法.
- 作为转移导向治疗的SBRT对于寡头进展需要在全身治疗管理的背景下进一步调查.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K